SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the return of "OG Memes" and 2021 vibes, fueled by bullish sentiment following recent market events. Community members are actively promoting its strong community and potential for significant growth, emphasizing the importance of conviction. Discussions also revolve around potential exchange listings and the revival of Rage Comics.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining traction as community members rally around its self-described "organic" and "deflationary" nature.   bridging and burning tokens, as well as potential staking opportunities. Bullish sentiment is high among holders, with many declaring it the "only option."

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to renewed discussions around a past AI server deal and its low float, leading to speculation of a potential short squeeze. Community members are actively watching key breakout levels, anticipating a move to higher price targets. The stock's previous run and current setup are fueling interest among traders looking for the next low-float runner.

Bondex is a web 3.0 professional network where users own part of the ecosystem earn rewards and monetise their network.

Bondex

Bondex ($BDXN) is trending as traders discuss its potential in the Web3 talent network, especially after a recent token unlock event that it weathered smoothly, signaling strong demand. The community is also excited about its growing trading volume and recent listing on Bybit Futures perpetual, with some drawing comparisons to early-stage Solana. Some users speculate that the Remote3 acquisition strengthens the project.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is trending as the community eagerly anticipates the launch of "AirLock," a feature designed to reward token holders and promote a strong hodling culture. Discussions highlight the potential for community-owned supply control and the team's commitment to exchange listings, driving excitement around the project's future within the Solana ecosystem.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the Cannabis and Plant Propagation segments. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Aurora Cannabis is trending as cannabis stocks react to reports that the Trump administration is considering loosening federal restrictions on marijuana, potentially reclassifying it as a Schedule III drug; this has ignited speculation about the impact on the sector. Community discussions focus on the potential benefits of reclassification, including access to banking services and reduced tax burdens, while some caution against overhyping the news until an official order is signed.

Berachain

Berachain ($BERA) is trending as the community discusses its Proof-of-Liquidity model and recent integrations, including PAW Chain and Bancor's Arb Fast Lane. Community members are debating its potential, TVL, and recent price action, while also watching for potential breakout points and exchange listings. Some users express concerns about token distribution, while others highlight positive aspects such as governance upgrades and real-world utility.

Codatta

XNY (Codatta) is gaining traction as traders discuss its potential for another significant surge, reminiscent of a prior 300% increase. Community members are closely watching its chart patterns, noting bullish formations and strong support levels, particularly in relation to Bitcoin's movements. Interest is also building around Codatta's role in AI data and its fingerprint verification technology.

Amplify ETF Trust - Amplify Seymour Cannabis ETF

Amplify Seymour Cannabis ETF

$CNBS is trending as cannabis stocks experience volatility amid discussions of potential federal regulatory changes, including reclassification, with some in the community pointing to executive action. The community is focused on the potential impacts of any changes, especially tax relief and banking access, while also scrutinizing sector leaders and potential market manipulation. Recent market activity and unusual options activity are also being closely monitored by investors.

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

FibroGen Inc

Recent insider buying, particularly by the CEO, and analyst reiteration of a Buy rating with a $10 price target are driving interest in FibroGen. Community members are actively discussing the upcoming reverse stock split and its potential impact, with some expressing concerns while others hope it will attract institutional investment. Anticipation surrounds the closing of the China sale to AstraZeneca, which is expected to improve FibroGen's cash position and extend its runway into 2027, allowing focus on oncology trials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period...

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 PR Newswire BELLEVUE, Wash., Dec. 1, 2025...

Cancer Immunotherapy Microcap Soars on Possible Major Licensing Deal

As pharmaceutical giants increasingly look outside their walls for breakthrough innovations, the licensing model has become the preferred pathway for bringing next-generation therapies to market. Biotech companies with promising platforms are commanding substantial upfront payments and milestone structures that can exceed $800 million, reflecting the pharmaceutical industry's appetite for differentiated assets that address significant unmet medical needs in oncology.Shares of OSR Holdings, Inc. (<a href="https://www.allpennystocks.com/stockquote/osrh" target="_blank">NASDAQ: OSRH</a>) are surging Friday after the company announced that its subsidiary Vaximm AG has entered a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement covering VXM01, Vaximm's first-in-class oral cancer immunotherapy platform.The proposed deal structure outlines significant financial terms that underscore the asset's commercial potential. Vaximm would receive a $20 million upfront payment upon execution of a definitive agreement, followed by up to $815 million in clinical, regulatory, and commercial milestone payments as the program advances through development and commercialization. Additionally, Vaximm would receive a pass-through of commercial royalties that BCME may collect from any future pharmaceutical partner, structured with a defined delta-recovery mechanism that allows BCME to recoup milestone differentials before royalty sharing commences.The term sheet establishes a six-month exclusivity period during which both parties will work toward finalizing a definitive licensing agreement, subject to customary due diligence and board approvals. Under the contemplated framework, BCME would function as a strategic financial intermediary, providing capital to fund the partnering and development activities necessary to secure a global out-license with a major pharmaceutical company. This approach mirrors structured financing models deployed by specialized life sciences investors including Royalty Pharma, Blackstone Life Sciences, and RTW Investments.According to Andreas Niethammer, incoming CEO of Vaximm AG, the term sheet represents an important milestone for advancing VXM01's development and global commercialization while allowing Vaximm to retain full ownership of its intellectual property. The structure enables the company to continue its mission of delivering innovative immunotherapies to patients worldwide with reduced dilution risk.Tim Smith, Head of Investor Relations at OSR Holdings, emphasized that Vaximm's oral T-cell platform represents a genuinely innovative approach in oncology with potential to transform cancer treatment. The exclusivity period with BCME reflects shared commitment to maximizing the global opportunity for VXM01, positioning the asset for a major pharmaceutical partnership that could unlock its full commercial potential.The term sheet also incorporates an optional blockchain-based royalty participation mechanism utilizing "TAC" tokens as an on-chain representation of future royalty revenue streams. Should Vaximm elect to draw development capital from the BCM Royalty Fund, a portion of VXM01 commercial royalties could be allocated to TAC token holders. If this option is not exercised, royalties would flow exclusively through the BCME pass-through structure.Vaximm's VXM01 platform employs a proprietary oral T-cell vaccination approach using live, attenuated bacterial vectors to deliver tumor-associated antigens and induce robust cellular immune responses. The lead candidate targets VEGFR-2 and has demonstrated clinical activity and safety across multiple cancer indications. BCME, a Switzerland-based life sciences investment entity, is currently OSR Holdings' largest shareholder.Shares of OSRH are up 25.8% at $0.57 in Friday afternoon trading. Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.View <a href='https://www.allpennystocks.com/specialreportsUS/4014/cancer-immunotherapy-microcap-soars-on-possible-major-licensing-deal'>more of this article</a> on AllPennyStocks.com.About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a>
Phone: (800) 558-4560 Ext: 101

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe...

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion OSR Holdings Appoints Scientific Co-Founder...

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor...

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care OSR Holdings Signs Definitive Agreement to Acquire...

OSR Holdings, Inc. operates as a global healthcare company. The firm engages in developing oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention of medical devices and systems distribution in Korea. Its products are offered through its subsidiaries. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

OSRH
OSR Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest OSRH News

OSRHOSR Holdings Inc